Search

451 Result(s)
Sort by

Kicking off 2024 with five new R&D partnerships

Kicking off 2024 with five new R&D partnerships

We are kicking off 2024 with five new R&D partnerships to further enable and accelerate the company’s commitment to transform the lives of patients world-wide.
H5N1: Bird flu again. What’s different now?

H5N1: Bird flu again. What’s different now?

H5N1: how is avian influenza now? The virus known for affecting wild & domestic birds has been detected in dairy cows in the US. What you need to know.
Sabine Reinig

Sabine Reinig

For Sabine, who leads Boehringer Ingelheim’s global people strategy, continuous development is the essence of a successful career. Clear aspirations and openness to new opportunities are her key ingredients.
Knowing the enemy: PRRS and PCVD

Knowing the enemy: PRRS and PCVD

The swine industry is constantly vigilant of viruses such as PRRS and PCV2 (PCVD). Learn about prevention, symptoms knowledge, and control measures to make a difference.
European Election: Europe needs our vote

European Election: Europe needs our vote

This week, over 400 million citizens from the 27 European Union (EU) Member States will be able to elect a new European Parliament. Our vote can help to make a better and stronger Europe..
Vaccine bluetongue virus serotype 3 sheep cattle

Vaccine bluetongue virus serotype 3 sheep cattle

BULTAVO 3™ is a new vaccine that protects cattle and sheep against bluetongue virus serotype 3 (BTV-3). BULTAVO 3™ is the first BTV-3 vaccine that prevents clinical signs and mortality.
Valerie Nock

Valerie Nock

My career challengeFunctional Areas at Boehringer Ingelheim
PRRS Research Award 2022

PRRS Research Award 2022

Bridging science and veterinary practice for swine health: The winners of the European PRRS Award 2022
Edda Dankmeyer

Edda Dankmeyer

Edda Dankmeyer is our Lead of Sustainable Development Communications. She tells us where her passion for sustainability comes from, why she joined us, and how sustainable development can be a key differentiator for the company.
FDA-approves-nintedanib-in-SSc-ILD

FDA-approves-nintedanib-in-SSc-ILD

FDA approves Ofev® as the first and only therapy in the U.S. to slow the rate of decline in pulmonary function in patients with systemic sclerosis-associated ILD
Heart Diseases in humans and animals

Heart Diseases in humans and animals

Humans and animals are more alike than different. Having a heart disease can affect us similarly, and the way to prevent it can work for all as well.